Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Entertainment
  • Real Estate
  • Business
  • Technology
  • Artificial Intelligence
  • Non-profit
ncarol.com

MyoStrain®, MyoStress™ Rapid Hyperventilation Breath-hold Maneuver Enables First-of-its-Kind Needle-Free Stress Protocol for the Accurate Detection of Myocardial Ischemia
ncarol.com/10113696

Trending...
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
Myocardial Solutions Logo
MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- A new peer-reviewed study accepted in the Journal of the American College of Cardiology: Cardiovascular Imaging validated Myocardial Solutions ("MSI") technologies MyoStrain and MyoStress in a new stress testing protocol utilizing a hyperventilation breath-hold (HVBH) maneuver to accurately detect myocardial ischemia. The article demonstrated MyoStrain's speed and sensitivity to successfully measure cardiac stress during a safe, simple breathing maneuver. This novel technique may provide clinicians with a faster and safer quantitative stress test to help improve the diagnosis and management of coronary artery disease without any pharmacological or physical stress protocols.[1]

Results showed the MyoStrain/MyoStress HVBH maneuver yielded greater accuracy over traditional stress testing methods for the detection of myocardial ischemia. HVBH exam times were significantly shorter and were performed without contrast agents or pharmacological stressors.

Dr. Marco Ochs, MD, Cardiologist at Theresien Hospital in Mannheim, Germany and lead author of the study, stated: "This study demonstrates the immense clinical utility MyoStrain's diagnostic speed and accuracy can bring to ischemic stress testing. Hyperventilation/breath-hold maneuver combined with MyoStrain/MyoStress provides a fast and safe scan procedure for clinicians to assess their patients without needing contrast agents or pharma stressors. The result is a 15-minute, needle-free MyoStress test designed to help advance ischemia detection, improve workflow efficiency and enhance the overall patient experience."

More on ncarol.com
  • Bryan Regan Photography shoots for GQ Magazine
  • Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy

Professor Matthias Friedrich, MD, FESC, FACC, MSCMR, Professor of Medicine and Chief of Cardiovascular Imaging at McGill University Health Centre in Montreal, Quebec, added: "There are numerous limitations concerning the safety, feasibility, logistical effort, and speed with today's stress testing techniques. We adapted the hyperventilation/breath-hold maneuver with MyoStrain to help overcome these limitations, providing a fast, safe and non-invasive approach to improve the cardiovascular assessment of patients suspected of coronary artery disease. This is a huge step."

John Funkhouser, CEO at MSI, stated: "There are over 10 million annual tests performed in the U.S. every year. The majority of stress testing is nuclear, which involves injecting radioactive agents into the patient. This procedure is not highly accurate and can take up to four hours of the patient's time to complete. MyoStress testing takes about 15 minutes, is totally non-invasive, and is highly accurate in finding ischemia caused by coronary heart diseases. This test could become a new standard of care in stress testing."

Access to the publication abstract is available here.

[1] Ochs, M et al. J Am Coll Cardiol Cardiovasc Imaging. Apr 14, 2021. DOI: 10.1016/j.jcmg.2021.02.022

More on ncarol.com
  • Designed for Healthcare: How TOLI Is Rethinking Functional Flooring
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • ICG Homes Breaks Ground on the Triangle's 2027 St. Jude Dream Home
  • KayeDinero Takes Viewers Above Asheville in "Autumn in the Blue Ridge" Aerial Visual
  • PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence

Media Contact
Ahmed Osman
[email protected]
919.459.9113

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI's proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

See original content: https://www.myocardialsolutions.com/news-article/myostrain-myostress-rapid-hyperventilation-breath-hold-maneuver-enables-first-of-its-kind-needle-free-stress-protocol-for-the-accurate-detection-of-myocardial-ischemia

SOURCE Myocardial Solutions, Inc.

Related Links

http://www.myocardialsolutions.com
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Asheville-Based KayeDinero Surpasses 100-Track Goal as Detroit Lions Win 35-10 in Munich
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • Nious Media Expands Gaming Coverage With 2026 Game & Geek Expo Special
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Dark Chocolate Nutcracker Marks 15 Years
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • After Nvidia's 14% Drop, Asheville Artist KayeDinero Releases "Nvidia"
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • Gabby Press Earns High Praise From BookLife For Book About the Dangers of Corporate AI
  • Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
  • CB Stuffer Announces Private Sale to Secure Future of Brand Growth
_catLbl0 _catLbl1

Popular on ncarol.com

  • Nious Media Expands Independent Entertainment Network Through Gaming, Music and Digital Storytelling - 228
  • Kestrel Ridge Health Launches AI-Powered Ophthalmology Workforce Forecasting Platform - 223
  • North Carolina Author Carrie Sybert Celebrates Three Published Books - 197
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki - 140
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs - 132
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration - 127
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers - 121
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA) - 120
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight - 112
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma - 109

Similar on ncarol.com

  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute